Howland Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.44M Buy
11,420
+42
+0.4% +$5.53K 0.05% 139
2026
Q1
$1.59M Buy
11,378
+312
+3% +$43.7K 0.06% 127
2025
Q4
$1.36M Buy
11,066
+1
+0% +$122 0.05% 136
2025
Q3
$1.23M Hold
11,065
0.05% 150
2025
Q2
$1.23M Hold
11,065
0.05% 146
2025
Q1
$1.24M Sell
11,065
-2,021
-15% -$209K 0.06% 140
2024
Q4
$1.21M Sell
13,086
-2,153
-14% -$194K 0.05% 140
2024
Q3
$1.28M Sell
15,239
-1,171
-7% -$89.4K 0.06% 139
2024
Q2
$1.13M Sell
16,410
-2,175
-12% -$145K 0.05% 134
2024
Q1
$1.36M Sell
18,585
-2,582
-12% -$199K 0.07% 120
2023
Q4
$1.71M Sell
21,167
-155
-0.7% -$12.1K 0.09% 107
2023
Q3
$1.6M Sell
21,322
-5,004
-19% -$385K 0.09% 107
2023
Q2
$2.03M Sell
26,326
-450
-2% -$35.9K 0.12% 95
2023
Q1
$2.22M Sell
26,776
-165
-0.6% -$13.7K 0.13% 90
2022
Q4
$2.31M Sell
26,941
-1,008
-4% -$79.8K 0.14% 89
2022
Q3
$1.72M Sell
27,949
-7,159
-20% -$451K 0.11% 96
2022
Q2
$2.17M Buy
35,108
+986
+3% +$61K 0.13% 82
2022
Q1
$2.03M Buy
34,122
+199
+0.6% +$12.7K 0.11% 85
2021
Q4
$2.46M Sell
33,923
-613
-2% -$42.2K 0.13% 80
2021
Q3
$2.41M Sell
34,536
-1,669
-5% -$117K 0.13% 87
2021
Q2
$2.49M Sell
36,205
-2,242
-6% -$150K 0.13% 85
2021
Q1
$2.48M Sell
38,447
-32,941
-46% -$2.12M 0.14% 83
2020
Q4
$4.16M Sell
71,388
-25,029
-26% -$1.51M 0.24% 68
2020
Q3
$6.09M Sell
96,417
-13,439
-12% -$932K 0.4% 58
2020
Q2
$8.45M Sell
109,856
-8,599
-7% -$659K 0.61% 51
2020
Q1
$8.86M Sell
118,455
-7,294
-6% -$504K 0.78% 47
2019
Q4
$8.17M Sell
125,749
-12,109
-9% -$789K 0.58% 55
2019
Q3
$8.74M Sell
137,858
-7,035
-5% -$460K 0.66% 51
2019
Q2
$9.79M Sell
144,893
-69,470
-32% -$4.57M 0.76% 46
2019
Q1
$13.9M Sell
214,363
-3,985
-2% -$265K 1.13% 32
2018
Q4
$13.7M Sell
218,348
-16,398
-7% -$1.15M 1.29% 30
2018
Q3
$18.1M Sell
234,746
-20,648
-8% -$1.56M 1.38% 25
2018
Q2
$18.1M Sell
255,394
-1,631
-0.6% -$115K 1.44% 22
2018
Q1
$19.4M Buy
257,025
+8,765
+4% +$697K 1.56% 20
2017
Q4
$17.8M Sell
248,260
-8,241
-3% -$626K 1.42% 24
2017
Q3
$20.8M Sell
256,501
-850
-0.3% -$65K 1.72% 21
2017
Q2
$18.2M Buy
257,351
+882
+0.3% +$58.7K 1.54% 23
2017
Q1
$17.4M Buy
256,469
+889
+0.3% +$62.5K 1.51% 23
2016
Q4
$18.3M Buy
255,580
+2,273
+0.9% +$169K 1.71% 19
2016
Q3
$20M Sell
253,307
-5,303
-2% -$431K 1.86% 16
2016
Q2
$21.6M Sell
258,610
-644
-0.2% -$57.2K 2.03% 13
2016
Q1
$23.8M Buy
259,254
+1,334
+0.5% +$120K 2.42% 5
2015
Q4
$26.1M Buy
257,920
+493
+0.2% +$51.3K 2.65% 3
2015
Q3
$25.3M Buy
257,427
+2,092
+0.8% +$232K 2.75% 3
2015
Q2
$29.9M Sell
255,335
-3,417
-1% -$373K 3.06% 1
2015
Q1
$25.4M Sell
258,752
-1,680
-0.6% -$171K 2.59% 3
2014
Q4
$24.5M Sell
260,432
-19,985
-7% -$2.07M 2.44% 4
2014
Q3
$29.9M Sell
280,417
-15,513
-5% -$1.52M 3.07% 2
2014
Q2
$24.5M Sell
295,930
-5,800
-2% -$451K 2.51% 4
2014
Q1
$21.4M Buy
301,730
+13,260
+5% +$1.04M 2.43% 5
2013
Q4
$21.7M Sell
288,470
-10,120
-3% -$705K 2.69% 3
2013
Q3
$18.8M Sell
298,590
-2,317
-0.8% -$138K 2.56% 3
2013
Q2
$15.4M Buy
+300,907
New +$15.7M 2.44% 4

Other funds holding GILD

Howland Capital Management's GILD Position: Q2 2026 in Review

Howland Capital Management increased its Gilead Sciences (GILD) stake by 0.37% in Q2 2026, buying an estimated $5.53K and bringing the position to 11,420 shares worth $1.44M. The position accounts for 0.05% of the portfolio, ranked #139.

Howland Capital Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $29.9M in Q2 2015. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Howland Capital Management held 11,420 shares of Gilead Sciences worth $1.44M as of Q2 2026.
  • Howland Capital Management bought 42 Gilead Sciences shares in Q2 2026, an estimated $5.53K.
  • Gilead Sciences made up 0.05% of Howland Capital Management's portfolio in Q2 2026, its #139 holding.
  • Howland Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Howland Capital Management's Gilead Sciences position peaked at $29.9M in Q2 2015.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Howland Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.